Fasting Study of Levothyroxine Sodium Tablets 300 Mcg to Synthroid® Tablets 300 Mcg
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's levothyroxine
sodium 300 mcg tablets to Abbott's Synthroid® 300 mcg tablets following a single, oral 600
mcg dose (2 × 300 mcg) administered under fasting conditions.